vs
Prestige Consumer Healthcare Inc.（PBH）とRapid7, Inc.（RPD）の財務データ比較。上の社名をクリックして会社を切り替えられます
Prestige Consumer Healthcare Inc.の直近四半期売上が大きい（$283.4M vs $217.4M、Rapid7, Inc.の約1.3倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 1.4%、差は15.0%）。Rapid7, Inc.の前年同期比売上増加率が高い（0.5% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $36.4M）。過去8四半期でRapid7, Inc.の売上複合成長率が高い（3.0% vs 1.2%）
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
Rapid7社は世界的に有名なサイバーセキュリティ企業で、脆弱性管理、脅威検知・対応、クラウドセキュリティ、セキュリティ分析などの総合的なソリューションを提供しています。テクノロジー、医療、金融、製造業などの各業種の企業や公共部門を顧客とし、サイバー脅威への効率的な対応を支援します。
PBH vs RPD — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $283.4M | $217.4M |
| 純利益 | $46.7M | $3.1M |
| 粗利率 | 55.5% | 68.9% |
| 営業利益率 | 29.1% | 1.0% |
| 純利益率 | 16.5% | 1.4% |
| 売上前年比 | -2.4% | 0.5% |
| 純利益前年比 | -23.5% | 44.1% |
| EPS（希薄化後） | $0.97 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $283.4M | $217.4M | ||
| Q3 25 | $274.1M | $218.0M | ||
| Q2 25 | $249.5M | $214.2M | ||
| Q1 25 | $296.5M | $210.3M | ||
| Q4 24 | $290.3M | $216.3M | ||
| Q3 24 | $283.8M | $214.7M | ||
| Q2 24 | $267.1M | $208.0M | ||
| Q1 24 | $277.0M | $205.1M |
| Q4 25 | $46.7M | $3.1M | ||
| Q3 25 | $42.2M | $9.8M | ||
| Q2 25 | $47.5M | $8.3M | ||
| Q1 25 | $50.1M | $2.1M | ||
| Q4 24 | $61.0M | $2.2M | ||
| Q3 24 | $54.4M | $15.4M | ||
| Q2 24 | $49.1M | $6.5M | ||
| Q1 24 | $49.5M | $1.4M |
| Q4 25 | 55.5% | 68.9% | ||
| Q3 25 | 55.3% | 70.2% | ||
| Q2 25 | 56.2% | 70.6% | ||
| Q1 25 | 57.3% | 71.7% | ||
| Q4 24 | 55.5% | 69.5% | ||
| Q3 24 | 55.5% | 70.6% | ||
| Q2 24 | 54.7% | 70.7% | ||
| Q1 24 | 54.8% | 70.3% |
| Q4 25 | 29.1% | 1.0% | ||
| Q3 25 | 29.1% | 2.7% | ||
| Q2 25 | 28.8% | 1.6% | ||
| Q1 25 | 29.8% | -0.0% | ||
| Q4 24 | 31.7% | 3.4% | ||
| Q3 24 | 29.7% | 6.0% | ||
| Q2 24 | 27.0% | 2.5% | ||
| Q1 24 | 29.7% | 4.7% |
| Q4 25 | 16.5% | 1.4% | ||
| Q3 25 | 15.4% | 4.5% | ||
| Q2 25 | 19.0% | 3.9% | ||
| Q1 25 | 16.9% | 1.0% | ||
| Q4 24 | 21.0% | 1.0% | ||
| Q3 24 | 19.2% | 7.2% | ||
| Q2 24 | 18.4% | 3.1% | ||
| Q1 24 | 17.9% | 0.7% |
| Q4 25 | $0.97 | $0.05 | ||
| Q3 25 | $0.86 | $0.15 | ||
| Q2 25 | $0.95 | $0.13 | ||
| Q1 25 | $1.00 | $0.03 | ||
| Q4 24 | $1.22 | $0.08 | ||
| Q3 24 | $1.09 | $0.21 | ||
| Q2 24 | $0.98 | $0.09 | ||
| Q1 24 | $0.98 | $0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $62.4M | $474.7M |
| 総負債低いほど良い | $1.0B | — |
| 株主資本純資産 | $1.8B | $154.7M |
| 総資産 | $3.5B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.4M | $474.7M | ||
| Q3 25 | $119.1M | $407.1M | ||
| Q2 25 | $139.5M | $511.7M | ||
| Q1 25 | $97.9M | $493.5M | ||
| Q4 24 | $50.9M | $521.7M | ||
| Q3 24 | $51.5M | $443.7M | ||
| Q2 24 | $34.3M | $442.6M | ||
| Q1 24 | $46.5M | $411.7M |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $1.8B | $154.7M | ||
| Q3 25 | $1.8B | $127.2M | ||
| Q2 25 | $1.9B | $90.4M | ||
| Q1 25 | $1.8B | $52.7M | ||
| Q4 24 | $1.8B | $17.7M | ||
| Q3 24 | $1.7B | $-5.1M | ||
| Q2 24 | $1.7B | $-52.6M | ||
| Q1 24 | $1.7B | $-86.4M |
| Q4 25 | $3.5B | $1.7B | ||
| Q3 25 | $3.4B | $1.7B | ||
| Q2 25 | $3.4B | $1.6B | ||
| Q1 25 | $3.4B | $1.6B | ||
| Q4 24 | $3.3B | $1.7B | ||
| Q3 24 | $3.3B | $1.6B | ||
| Q2 24 | $3.3B | $1.5B | ||
| Q1 24 | $3.3B | $1.5B |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.3M | $37.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $75.3M | $36.4M |
| FCFマージンFCF / 売上 | 26.6% | 16.8% |
| 設備投資強度設備投資 / 売上 | 1.1% | 0.5% |
| キャッシュ転換率営業CF / 純利益 | 1.68× | 12.01× |
| 直近12ヶ月FCF直近4四半期 | $267.2M | $146.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.3M | $37.6M | ||
| Q3 25 | $57.5M | $39.0M | ||
| Q2 25 | $79.0M | $47.5M | ||
| Q1 25 | $61.8M | $29.8M | ||
| Q4 24 | $65.1M | $63.8M | ||
| Q3 24 | $69.8M | $44.0M | ||
| Q2 24 | $54.8M | $32.9M | ||
| Q1 24 | $66.9M | $31.1M |
| Q4 25 | $75.3M | $36.4M | ||
| Q3 25 | $55.4M | $34.8M | ||
| Q2 25 | $78.2M | $46.6M | ||
| Q1 25 | $58.4M | $28.4M | ||
| Q4 24 | $63.5M | $62.6M | ||
| Q3 24 | $67.8M | $42.6M | ||
| Q2 24 | $53.6M | $32.6M | ||
| Q1 24 | $63.8M | $30.4M |
| Q4 25 | 26.6% | 16.8% | ||
| Q3 25 | 20.2% | 16.0% | ||
| Q2 25 | 31.3% | 21.8% | ||
| Q1 25 | 19.7% | 13.5% | ||
| Q4 24 | 21.9% | 28.9% | ||
| Q3 24 | 23.9% | 19.9% | ||
| Q2 24 | 20.1% | 15.7% | ||
| Q1 24 | 23.0% | 14.8% |
| Q4 25 | 1.1% | 0.5% | ||
| Q3 25 | 0.8% | 1.9% | ||
| Q2 25 | 0.3% | 0.4% | ||
| Q1 25 | 1.2% | 0.6% | ||
| Q4 24 | 0.5% | 0.5% | ||
| Q3 24 | 0.7% | 0.6% | ||
| Q2 24 | 0.4% | 0.1% | ||
| Q1 24 | 1.1% | 0.3% |
| Q4 25 | 1.68× | 12.01× | ||
| Q3 25 | 1.36× | 3.97× | ||
| Q2 25 | 1.66× | 5.70× | ||
| Q1 25 | 1.23× | 14.14× | ||
| Q4 24 | 1.07× | 29.36× | ||
| Q3 24 | 1.28× | 2.85× | ||
| Q2 24 | 1.12× | 5.03× | ||
| Q1 24 | 1.35× | 22.10× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
